Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

VISTA, A Novel Mouse Ig Superfamily Ligand That Negatively Regulates T Cell Responses

L. Wang, R. Rubinstein, J. L. Lines, A. Wasiuk, Cory Ahonen, Y. Guo, L. Lu, David Gondek, Y. Wang, R. Fava, A. Fiser, S. Almo, R. Noelle
Published 2011 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
VISTA suppresses T cell proliferation and cytokine production and can influence autoimmunity and antitumor responses in mice.
This paper references
10.1084/jem.20050019
A critical role for the programmed death ligand 1 in fetomaternal tolerance
I. Guleria (2005)
10.1007/s00262-004-0593-x
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
Christian Blank (2004)
10.1016/0022-1759(95)00194-8
Cleavable CD40Ig fusion proteins and the binding to sgp39.
D. Hollenbaugh (1995)
10.1161/CIRCULATIONAHA.107.709360
Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8+ T-Cell–Mediated Injury in the Heart
Nir Grabie (2007)
10.1016/1074-7613(95)90125-6
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
10.1126/science.270.5238.985
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
10.1002/eji.200324228
Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses
S. Liang (2003)
10.1016/J.IT.2006.02.001
The PD-1-PD-L pathway in immunological tolerance.
T. Okazaki (2006)
10.1016/S0969-2126(00)00528-1
Dimeric structure of the coxsackievirus and adenovirus receptor D1 domain at 1.7 A resolution.
M. V. van Raaij (2000)
Noelle designed research, analyzed data, and wrote the manuscript Almo performed sequence homology, wrote the sections on structural experiments, and performed the structural analysis
L Author (2010)
10.1084/jem.20051776
Tissue expression of PD-L1 mediates peripheral T cell tolerance
M. Keir (2006)
10.1016/S1074-7613(00)80089-8
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H. Nishimura (1999)
10.1093/bioinformatics/btl449
MMM: a sequence-to-structure alignment protocol
B. K. Rai (2006)
Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154.
M. Mackey (1997)
10.1093/bioinformatics/16.6.566
DaliLite workbench for protein structure comparison
L. Holm (2000)
10.1016/J.IMMUNI.2007.05.016
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
M. Butte (2007)
The authors have no competing financial interests
10.1371/journal.pone.0004345
Using Sequence Similarity Networks for Visualization of Relationships Across Diverse Protein Superfamilies
H. J. Atkinson (2009)
10.1073/pnas.012025199
Large-scale analysis of the human and mouse transcriptomes
A. Su (2002)
10.1016/0165-5728(82)90034-0
Experimental autoimmune encephalomyelitis: An anatomically-based explanation of clinical progression in rodents
R. D. Simmons (1982)
10.1093/bioinformatics/btm404
Clustal W and Clustal X version 2.0
Mark A. Larkin (2007)
This work is supported by National Institutes of Health grants
10.1182/BLOOD.V92.10.3829.422K14_3829_3840
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
X. Zhang (1998)
10.1016/S1074-7613(03)00152-3
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity.
G. Sica (2003)
10.1073/pnas.0804453105
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
E. Lázár-Molnár (2008)
10.1016/J.IMMUNI.2005.01.016
Regulatory T cell lineage specification by the forkhead transcription factor foxp3.
J. Fontenot (2005)
The B 7 family re - visited
M. J. Ansari (2005)
10.1016/S1074-7613(00)80333-7
B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation.
F. Borriello (1997)
10.1038/35051100
ICOS co-stimulatory receptor is essential for T-cell activation and function
C. Dong (2001)
10.1146/annurev.immunol.26.021607.090331
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
10.1002/ijc.21795
HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD‐1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma
Hui Geng (2006)
Regulatory T cell lineage specification by the forkhead transcription factor foxp 3
G. M. Zhang (2005)
10.1158/0008-5472.CAN-03-3259
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
Christian Blank (2004)
10.1007/s00109-003-0430-2
B7-H1 pathway and its role in the evasion of tumor immunity
H. Dong (2003)
10.1038/nprot.2006.285
Active induction of experimental allergic encephalomyelitis
I. Stromnes (2006)
10.1093/bioinformatics/15.4.305
ESPript: analysis of multiple sequence alignments in PostScript
P. Gouet (1999)
10.1038/nm0902-1039c
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
10.1146/ANNUREV.IMMUNOL.23.021704.115611
The B7 family revisited.
R. Greenwald (2005)
10.1073/pnas.1133443100
Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein
C. Breithaupt (2003)
10.1084/jem.20022119
Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis
A. Salama (2003)
10.1093/nar/gkm988
Ensembl 2008
P. Flicek (2008)
10.1038/nprot.2006.284
Passive induction of experimental allergic encephalomyelitis
I. Stromnes (2006)
10.1084/jem.20022125
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
M. J. Ansari (2003)
10.1016/S0022-1759(98)00204-X
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.
M. B. Lutz (1999)
10.1038/ni1359
Ancient evolutionary origin of diversified variable regions demonstrated by crystal structures of an immune-type receptor in amphioxus
J. H. Prada (2006)
10.1101/GR.1239303
Cytoscape: a software environment for integrated models of biomolecular interaction networks.
P. Shannon (2003)
Lymphoproliferation in CTLA4deficient mice is mediated by costimulationdependent activation of CD 4 + T cells
U. A. Temann (1997)
10.1093/NAR/18.23.7025
Isolation and characterization of a variant dihydrofolate reductase cDNA from methotrexate-resistant murine L5178Y cells.
R. McIvor (1990)
10.4049/jimmunol.169.10.5538
Expression of Programmed Death 1 Ligands by Murine T Cells and APC1
T. Yamazaki (2002)
10.1073/PNAS.0307252101
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
Y. Latchman (2004)
10.1073/pnas.0712278105
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
D. Y. Lin (2008)
10.1016/S0022-1759(02)00013-3
A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells.
Y. Son (2002)
10.1073/pnas.192461099
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Yoshiko Iwai (2002)
10.4049/jimmunol.179.8.5064
PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues1
M. Keir (2007)
10.1126/SCIENCE.291.5502.319
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H. Nishimura (2001)
10.1093/nar/28.1.235
The Protein Data Bank
H. Berman (2000)
10.1016/S1074-7613(00)80406-9
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.
Cynthia A Chambers (1997)
Nucleic Acids Res
P Flicek (2008)
10.1016/S0022-2836(05)80360-2
Basic local alignment search tool.
S. Altschul (1990)
10.1084/jem.20090681
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
Cameron S. Brandt (2009)
10.1038/nri2326
Inhibitory B7-family molecules in the tumour microenvironment
W. Zou (2008)
10.1038/45582
T-cell co-stimulation through B7RP-1 and ICOS
S. K. Yoshinaga (1999)
10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9
PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2
LauraL Carter (2002)
10.1038/276269A0
A better cell line for making hybridomas secreting specific antibodies
M. Shulman (1978)
10.1093/bioinformatics/btp302
pGenTHREADER and pDomTHREADER: new methods for improved protein fold recognition and superfamily discrimination
Anna E. Lobley (2009)
10.1002/prot.20835
Multiple mapping method: A novel approach to the sequence‐to‐structure alignment problem in comparative protein structure modeling
B. K. Rai (2006)
10.1073/pnas.0710441105
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells
L. Wang (2008)



This paper is referenced by
10.1080/2162402X.2018.1469594
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
L. Wang (2018)
10.1371/journal.pone.0065531
The Immunoglobulin Superfamily Protein Differentiation of Embryonic Stem Cells 1 (Dies1) Has a Regulatory Role in Preadipocyte to Adipocyte Conversion
Gang Ren (2013)
10.1073/pnas.1407447111
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
L. Wang (2014)
Microenvironment and Immunology VISTA Is an Immune Checkpoint Molecule for Human T Cells
J. L. Lines (2014)
10.1093/intimm/dxx070
The immune checkpoint molecule VISTA regulates allergen-specific Th2-mediated immune responses
T. Ohno (2018)
Targeting IgV-like Domain Immune Checkpoint Receptors with Novel Nucleic Acid and Protein-Based Therapeutics
Aaron Prodeus (2018)
10.1016/j.molonc.2015.10.008
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
A. Śledzińska (2015)
10.3390/pharmaceutics12070663
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
Lukas Amon (2020)
Modulateurs vista de diagnostic et de traitement de cancer
Randolph J. Noelle (2013)
10.1007/s13238-019-0642-z
Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy
Shanjuan Hong (2019)
10.1007/s00109-020-01968-x
Exploring the VISTA of microglia: immune checkpoints in CNS inflammation
M. Borggrewe (2020)
10.1038/s41379-019-0364-z
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma
S. Muller (2019)
10.1089/VIM.2016.0125
The Role of Myeloid-Derived Suppressor Cells in Viral Infection.
A. O'ConnorMegan (2017)
10.1080/13543776.2016.1176150
Immune checkpoint inhibitors: a patent review (2010-2015)
Matthieu Collin (2016)
10.1002/med.21632
Targeting B7‐1 in immunotherapy
R. Chen (2019)
10.3390/cancers12030738
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
R. Vaddepally (2020)
10.1016/j.ccell.2015.03.001
Immune checkpoint blockade: a common denominator approach to cancer therapy.
S. Topalian (2015)
2D kinetic study of of PD-1 interaction and its inhibition of T-cell antigen recognition
Kaitao Li (2016)
10.3390/cancers11050628
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Sebastian Chrétien (2019)
10.1016/j.smim.2019.101308
VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
Mohamed A. ElTanbouly (2019)
10.1016/j.immuni.2016.05.002
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
F. Schildberg (2016)
10.1038/modpathol.2017.89
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
10.2147/OTT.S282530
Emerging Targets of Immunotherapy in Gynecologic Cancer
H. Cheng (2020)
10.1007/s00018-020-03459-1
Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer
S. Jafari (2020)
10.1126/science.aaz7741
Enforcing T cell innocence
C. Brown (2020)
10.1038/cmi.2017.16
A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma
H. Liu (2018)
10.4018/978-1-7998-6530-8.ch001
Cancer Immunotherapy: Beyond Checkpoint Inhibitors
Mohammad Raghibul Hasan (2021)
10.1038/s41423-020-00586-4
Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.
P. Martín (2020)
10.1016/j.jid.2016.10.049
Immune Checkpoint Molecule, VISTA Regulates T-Cell-Mediated Skin Inflammatory Responses.
T. Ohno (2017)
10.18632/oncotarget.17232
PD1 signal transduction pathways in T cells.
H. Arasanz (2017)
10.1038/ncomms5432
An intestinal commensal symbiosis factor controls neuroinflammation via TLR2-mediated CD39 signaling
Y. Wang (2014)
10.1038/nrrheum.2016.131
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
M. Vlist (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar